<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01937559</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00021253</org_study_id>
    <nct_id>NCT01937559</nct_id>
  </id_info>
  <brief_title>Topical Tranexamic Acid (TXA) in Joint Arthroplasty</brief_title>
  <official_title>Topical Application of Tranexamic Acid in Joint Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hawkins Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hawkins Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy of topical tranexamic acid (TXA) in
      decreasing blood loss following both shoulder arthroplasty and primary total hip
      arthroplasty. TXA functions to decrease blood loss by affecting the blood clotting system
      within the body. The investigators hypothesize that topical application of TXA prior to
      closure reduces postoperative bleeding as measured by absolute changes in postoperative
      hemoglobin levels and surgical drain output. In addition, use of topically applied
      tranexaminic acid may reduce the need for transfusions, the rates of hematomas, infections,
      and length of hospital stay.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative blood loss</measure>
    <time_frame>Duration of hospital stay</time_frame>
    <description>Blood loss will be calculated as the difference between the preoperative hemoglobin and the lowest postoperative hemoglobin during the hospital stay or the lowest postoperative hemoglobin prior to blood transfusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perioperative blood transfusions</measure>
    <time_frame>Duration of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of blood units transfused</measure>
    <time_frame>Duration of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of surgical infections</measure>
    <time_frame>Duration of hospital stay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Duration of hospital stay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until start of rehabilitation program</measure>
    <time_frame>Up to 3 weeks post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative changes in joint function</measure>
    <time_frame>Duration of hospital stay</time_frame>
    <description>Increase or reduction in ROM of the knee will be accounted for during the patient's stay at the hospital post-surgery.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Shoulder outcome scores</measure>
    <time_frame>6 months post-surgery</time_frame>
    <description>Shoulder outcome scores will include a PENN derived ASES form.</description>
  </other_outcome>
  <other_outcome>
    <measure>General outcome scores</measure>
    <time_frame>6 months post-surgery</time_frame>
    <description>General outcome measures will include EQ-5D, GROC and SANE forms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Hip outcome scores</measure>
    <time_frame>6 months</time_frame>
    <description>Hip outcome measurements will include Harris Hip score and the WOMAC forms.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Hip Arthropathy</condition>
  <condition>Shoulder Arthropathy</condition>
  <arm_group>
    <arm_group_label>Antifibrinolytic agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tranexaminic acid (TXA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tranexaminic Acid (TXA)</intervention_name>
    <description>1.5g of TXA in 100ml normal saline solution</description>
    <arm_group_label>Antifibrinolytic agent</arm_group_label>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Shoulders: All adult patients over the age of 18 scheduled for a primary total
             arthroplasty or a primary reverse shoulder arthroplasty will be eligible for inclusion
             in the study.

        Hips: All adult patients over the age of 18 scheduled for a primary total hip arthroplasty
        will be eligible for inclusion in the study.

        Exclusion Criteria:

          -  allergy to TXA, refusal of blood products, preoperative use of anticoagulant therapy
             within 5 days of surgery, history of seizures, renal failure (creatine clearance
             &lt;30ml/min), bleeding disorders, venous thromboembolism (deep vein thrombosis and/or
             pulmonary embolism), significant cardiac history (myocardial infarction, angina,
             stroke, lower limb ischemia), or perioperative anemia (hemoglobin &lt;11g/dl in females
             and &lt; 12g/dl in males).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Burnikel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steadman Hawkins Clinic of the Carolinas - Greenville Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyle Adams, BS</last_name>
    <phone>864-454-7458</phone>
    <email>kyle.adams@hawkinsfoundation.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Steadman Hawkins Clinic of the Carolinas - Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlisle Shealy, MD</last_name>
      <phone>864-454-7458</phone>
      <email>carlisle.shealy@hawkinsfoundation.com</email>
    </contact>
    <investigator>
      <last_name>Brian Burnikel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard J Hawkins, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael J Kissenberth, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Tolan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brayton R Shirley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Phillip H Wessinger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2013</study_first_submitted>
  <study_first_submitted_qc>September 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2013</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tranexaminic acid (TXA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

